Announcements – Neville Registrars

26 JUNE 2020

Neville Registrars welcomes Jaywing plc

Neville Registrars is delighted to welcome Jaywing plc as the newest addition to its list of client companies. Jaywing plc is an agency and consulting business with its headquarters in Sheffield. The Company operates in the UK and Australia and specialises in Data Science. Further information can be found on the Company's……

17 JUNE 2020

Panoply Holdings PLC : Contract as part of major UK Government project

RNS Number : 1632Q Panoply Holdings PLC (The) 17 June 2020 17 June 2020 RNS Reach The Panoply Holdings PLC ("The Panoply", the "Group", and the "Company") New contract as part of major UK Government project The Panoply (AIM: TPX), the technology-enabled services group focused on……

15 JUNE 2020

Croma Sec. Sol. Grp : Contract Renewal and Uplift

RNS Number : 8885P Croma Security Solutions Group PLC 15 June 2020 15 June 2020 CROMA SECURITY SOLUTIONS GROUP PLC ("CSSG" or the "Company") Renewal and Uplift to Contact Now Worth £5 million Annually Croma Security Solutions Group Plc is very pleased to announce it has been awarded……

15 JUNE 2020

Crimson Tide PLC : Significant Contract Win

RNS Number : 9660P Crimson Tide PLC 15 June 2020 Crimson Tide Plc Significant contract win Crimson Tide Plc (TIDE) ("Crimson Tide" or "The Company") announces a major contract win with one of Britain's leading neighbourhood retailers. The contract for the Company's mpro5 mobile app platform, is for five……

RNS Number : 9660P

Crimson Tide PLC

15 June 2020

Crimson Tide Plc

Significant contract win

Crimson Tide Plc (TIDE) ("Crimson Tide" or "The Company") announces a major contract win with one of Britain's leading neighbourhood retailers. The contract for the Company's mpro5 mobile app platform, is for five years and exceeds £1.6m in total contracted revenue. In terms of gross revenue, this represents mpro5's second largest contract.

mpro5 will be used in the client's shops to handle reactive and predictive maintenance reporting. Staff will be able to use mpro5 to alert cleaning and maintenance contractors to requirements in real time. Mpro5's rich reporting, alerting and dashboard capabilities will help inform the client as to shop performance, cleanliness and safety.

mpro5's IoT (Internet of Things) module is included in this contract and will assist with supplying temperature readings, allowing jobs and flows to be scheduled automatically from sensor data.

Barrie Whipp, Founder & Chairman, commented "mpro5 stands out as the leading mobile app platform in this sector and the bona fides and service quality that we have established served us well during the sales process. We continue to trade strongly in the current environment and the pipeline for mpro5 remains high."

For further information:

Crimson Tide plc

Barrie Whipp / Luke Jeffrey

01892 542 444

finnCap Ltd (Nominated Adviser and Broker) Julian Blunt / James Thompson – Corporate Finance Andrew Burdis – Corporate Broking

020 7220 0500

Alma PR

Josh Royston / Harriet Jackson

020 3405 0213

For further information on Crimson Tide plc, see the website at: www.crimsontide.co.uk/

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

CNTFAMLTMTJBMLM

Close

02 JUNE 2020

Trident Resources : Admission to AIM and First Day of Dealings

RNS Number : 6054O Trident Resources Plc 02 June 2020 2 June 2020 TRIDENT RESOURCES PLC ("Trident" or the "Company") Admission to trading on AIM and First Day of Dealings Trident Resources plc (to be renamed Trident Royalties plc), a new growth……

RNS Number : 6054O

Trident Resources Plc

02 June 2020

2 June 2020

TRIDENT RESOURCES PLC

("Trident" or the "Company")

Admission to trading on AIM and First Day of Dealings

Trident Resources plc (to be renamed Trident Royalties plc), a new growth focused mining royalty and streaming company, is pleased to announce the admission of its ordinary shares of 1p each ("Ordinary Shares") to trading on the AIM Market of the London Stock Exchange ("Admission"). Dealings will commence, at 8.00 a.m. today under the ticker symbol TRR and ISIN: GB00BF7J2535.

The Company's Admission to AIM follows a successful placing, raising gross proceeds of £16 million (approximately US$20 million) from the issue of 80,000,000 Ordinary Shares (the "Placing") at a price of 20p per share (the "Placing Price").

HIGHLIGHTS

· Trident plans to rapidly establish itself as a diversified mining royalty and streaming company by constructing a portfolio to broadly mirror the commodity exposure of the global mining sector, with a bias towards production or near-production assets;

· Raised gross proceeds of £16 million (approximately US$20 million) via a placing of 80,000,000 Ordinary Shares at a price of 20p per share;

· On Admission, the Company will have 103,500,000 Ordinary Shares in issue, giving it a market capitalisation at the Placing Price of approximately £20.7 million (approximately US$25.8 million);

· Once scale has been achieved, the Company expects strong cash generation to support an attractive dividend policy, providing investors with a desirable mix of inflation protection (through exposure to commodities), capital growth and income;

· Shareholder base includes leading institutional investors such as LIM Asia Special Situations Master fund, Regal Funds Management, Tribeca Investment Partners and Terra Capital Natural Resources Fund.

Adam Davidson, Chief Executive Officer of Trident commented:

"With the completion of our recently announced £16 million equity financing and AIM admission, we have developed a strong platform from which to deliver our strategy. Our focus is now on executing on our pipeline of transactions and assessing new opportunities, ranging from new primary transactions to the acquisition of existing royalty and streaming assets, as well as portfolio transactions in the secondary market.

We look forward to life as an AIM quoted royalty and streaming company and will be updating shareholders on our further progress in due course."

James Kelly, Non-Executive Chairman of Trident commented:

"Our fundraising represents the largest equity placing associated with a new listing in any sector across the London markets in over three months, an outstanding achievement for a new offering in the context of such difficult general market conditions. I believe that this underscores the strength of both our strategy and management team and we now look forward to executing on our growth plans.

On behalf of Trident's board of directors, I would like to extend my thanks to Adam and his team, our existing shareholders, incoming investors and our adviser team for their support, hard work and dedication in helping us get to this point."

ROYALTY & STREAMING STRATEGY

· Trident considers mining royalty and streaming assets to represent an attractive opportunity for investors, providing exposure to commodity prices with a typically lower risk profile than mining equities, allowing participation in growth from development and exploration expenditure, without the associated cost or dilution to the holder of the royalty or stream;

· Strategy to participate in what Trident believes is a strong growth market for alternative finance in the mining sector by writing new royalties and streams, as well as consolidation of existing royalties and streams available on attractive terms, taking advantage of gaps in the market under-exploited by other mining royalty and streaming companies;

· Trident aims to assemble a portfolio of royalty and streaming assets to provide investors with exposure to a mix of base and precious metals, bulk materials (excluding thermal coal) and battery metals, differentiating Trident from the majority of its peers which are exclusively, or heavily weighted, to precious metals;

· Trident will seek to acquire royalties and streams across a range of mining-friendly jurisdictions worldwide, while most other royalty and streaming companies have portfolios weighted towards mining assets located in North and South America;

· Targeting attractive small-to-mid size transactions which are often ignored in a sector dominated by large players;

· Trident believes that the acquisition and aggregation of individual royalties and streams has the potential to deliver strong returns for shareholders as assets are acquired on terms reflective of single asset risk compared with the lower risk profile of a diversified, larger scale portfolio, including diversity as to geography (lowering geopolitical risks) and commodity exposure;

· Producing royalties and streams can deliver strong and predictable cash flows, which can be leveraged through debt to enhance returns to equity and can underpin eventual dividend returns to shareholders. In this regard, the Company has entered into an exclusive mandate letter with Tribeca Global Resources Credit in relation to the arranging, underwriting and raising of an acquisition debt facility of up to approximately US$10 million;

· First royalty acquisition, expected to complete shortly, is a 1.5% free on board royalty over part of the producing Koolyanobbing Iron Ore Operation in Western Australia, operated by Mineral Resources Limited (ASX: MIN, market capitalisation approx. US$2.5 billion), providing exposure to an immediately cash generative royalty over an established asset which is currently undergoing a production increase;

· Trident has a pipeline of attractive follow-on transactions with further acquisitions expected to be announced in the near term;

· Trident intends to maintain a low overhead model, capable of supporting a larger scale business without a commensurate increase in operating expenses. In the first 12 months following Admission, total operating expenditure (excluding any deal related costs or costs associated with performance related bonus payments) are expected to be approximately US$1 million.

ADMISSION DOCUMENT

The Admission Document prepared by the Company in connection with Admission is available at the Company's website: www.tridentroyalties.com. Hard copies of the Admission Document are also available during normal business hours at the Company's registered offices: 2 Stone Building, Lincoln's Inn London WC2A 3TH.

CHANGE OF NAME

The Company has applied to Companies House to change its name to Trident Royalties Plc. The restrictions on working that have been imposed in response to the Covid-19 pandemic have resulted in a delay to the processing of change of name applications by Companies House and the Company does not have a firm date when this is expected to be completed. A further announcement will be made once the Company has received its change of name certificate and the change of name becomes effective.

TOTAL VOTING RIGHTS

For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), following Admission, Trident will have 103,500,000 Ordinary Shares in issue with voting rights attached. Trident holds no shares in treasury. This figure of 103,500,000 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the DTRs.

ADVISERS

Tamesis Partners LLP, Ashanti Capital Pty Ltd and Azure Capital Ltd are acting as financial advisers to the Company and Joint Book Runners to the Placing. Grant Thornton UK LLP is acting as Nominated Adviser. Bryan Cave Leighton Paisner LLP acted as UK legal counsel, Charles Russell Speechlys LLP as legal counsel to the Nominated Adviser and Joint Book Runners and PKF Littlejohn LLP acted as reporting accountant.

For more information on the Company please visit: www.tridentroyalties.com and follow the Company o n Twitter and LinkedIn

ENQUIRIES

Trident Resources Plc

Adam Davidson

www.tridentroyalties.com

+1 (757) 208-5171

Grant Thornton LLP (Nominated Adviser)

Colin Aaronson/ Richard Tonthat / Seamus Fricker

www.grantthornton.co.uk

+44 207 383 5100

Tamesis Partners LLP (Financial Adviser and Broker)

Richard Greenfield

www.tamesispartners.com

+44 203 882 2868

Yellow Jersey (Public Relations)

Charles Goodwin

www.yellowjerseypr.com

+44 7747 788 221

Azure Capital Ltd (Financial Adviser)

John Toll

www.azurecapital.com.au

+61 8 6263 0888

Ashanti Capital Pty Ltd (Financial Adviser)

Rob Hamilton

www.ashanticapital.com.au

+61 8 6169 2668

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation EU No. 596/2015. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

STRFBMMTMTIMTRM

Close

29 MAY 2020

Neville Registrars welcomes Craven Industrial Holdings Plc

Neville Registrars is delighted to welcome Craven Industrial Holdings Plc as the newest addition to its list of client companies. Craven Industrial is an un-quoted public investment company. …

28 MAY 2020

N4 Pharma PLC : Covid-19 Project Update

RNS Number : 1420O N4 Pharma PLC 28 May 2020 28 May 2020 N4 Pharma plc ("N4 Pharma", the "Company" or the "Group") Covid-19 Project Update Further to the Company's announcement on 16 April 2020, N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®,……

RNS Number : 1420O

N4 Pharma PLC

28 May 2020

N4 Pharma plc

("N4 Pharma", the "Company" or the "Group")

Covid-19 Project Update

Further to the Company's announcement on 16 April 2020, N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an update on the progress of its Covid-19 proof of concept work for Nuvec®.

As previously announced, the Company appointed Evotec International Gmbh ("Evotec") to undertake the Nuvec® proof of concept work. The Company can confirm that the first phase of the project has been carried out, within the expected timeframe, and that the plasmid DNA has been successfully amplified to produce sufficient material for the rest of the project and has been tested to confirm it matches the required specification. Evotec has also used this batch of the plasmid DNA to express the Covid-19 spike protein to be used as a positive control for the studies. Evotec will now move to the second phase of the work and start the in-vitro testing of Nuvec® as planned, during the first week of June 2020. This phase is expected to last approximately ten weeks.

The third phase of the in-vivo protein expression testing will be to undertake an initial pre in-vivo study to demonstrate expression of the spike protein in target cells in a murine target. Following the recent fundraise, announced on 13 May 2020, the Company is now also exploring ways in which it can bring forward the start of certain areas of this third phase to run alongside the in-vitro work.

Enquiries:

N4 Pharma Plc

Nigel Theobald, CEO

Via Scott PR

Allenby Capital Limited

James Reeve/Asha Chotai

Tel: +44(0)203 328 5656

Turner Pope Investments (TPI) Ltd

Andrew Thacker

Tel: +44(0)20 3657 0050

Scott PR

Georgia Smith

Tel: +44(0)1477 539 539

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

UPDGZGZKGNRGGZZ

Close

27 MAY 2020

Plant Health Care : Update on PHC279 2019 Field Trials

RNS Number : 9614N Plant Health Care PLC 27 May 2020 RNS 27 May 2020 PLANT HEALTH CARE plc ("Plant Health Care" or the "Company") Update on PHC279 2019 Field Trials Plant Health Care®, a leading provider of novel patent-protected biological products to……

RNS Number : 9614N

Plant Health Care PLC

27 May 2020

RNS

27 May 2020

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

Update on PHC279 2019 Field Trials

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update on its completed 2019 field trials of the PREtec peptide PHC279 for the control of plant diseases in corn, wheat and lettuce crops.

Highlights:

US Corn

– PHC 279 increased corn yields by 9-15% when applied as a foliar spray, creating potential grower value of $54 – $82 per acre at current average prices.

– PHC279 significantly improved the control of two key corn diseases by as much as 50%, even under heavy disease pressure.

Spring wheat

– PHC279 increased yield by as much as 17% when added to the standard disease control program, which is worth $86 per acre at current prices.

Lettuce

– PHC279 increased yield by as much as 22% compared to fungicides alone.

– PHC279 also improved disease control as much as 31% following foliar application.

In the US, 91m acres of corn were planted in 2019. Severe southern rust disease can routinely reduce corn yields as much as 25 bushels per acre. At current prices, this would equate to lost revenue for the farmer of $79 per acre. In historical epidemics of southern corn leaf blight, yields were reduced by 20 to 25 percent nationwide, resulting in an estimated $1 billion loss in harvest. In the Company's trials, when PHC279 was applied together with a leading chemical fungicide, it significantly improved control of both diseases compared to the fungicide treatment alone, and yields were increased by as much as 26 bushels per acre depending on application timing. Even a more modest benefit of 5-10 bushels per acre is likely to provide an attractive return on investment in the potential range of 5:1 to 8:1 for farmers who apply PHC279 to their fields.

In the UK, when PHC279 was applied to spring wheat seeds prior to planting, followed by adding it to the standard spray fungicide program, yield was increased by as much as 17% in fields with Septoria tritici blotch, the major disease of wheat in the UK. At current prices, this yield benefit would be worth $86 per acre to the farmer.

Lettuce drop disease is a major pathogen affecting US lettuce cultivation. In a series of US field trials inoculated with Sclerotinia , the causative agent of lettuce drop disease, PHC279 treated plants yielded as much as 22% more than plants treated only with the standard chemical fungicide program. With an acre of lettuce worth more than $10,000 in the US in 2018, even a modest increase in lettuce yield will likely justify the cost of applying PHC279.

Plant Health Care's PREtec peptides stimulate the plant to defend itself. Derived from natural proteins, this is a novel, environmentally friendly approach to protecting crops and increasing yields, compatible with mainstream agricultural practice. PHC279 may allow farmers to reduce applications of toxic fungicides or to achieve better control of disease.

Gary L. Cloud, Ph.D., a research agronomist and owner of GLC Consulting, Inc. participated in the testing of PHC279 in corn this season, and offered the following, "There was heavy disease pressure and PHC279 provided visible improvement in disease control and higher yield compared to the standard fungicide when applied early in the growing season. That is somewhat amazing due to the time that elapsed between application and harvest. I believe PHC279 will be a valuable tool for corn growers struggling to control disease in their fields."

Chris Richards, CEO of Plant Health Care, said "We are extremely encouraged with the performance of PHC279 in multiple key crops. Building on our recent success with PHC279 for the control of Asian soybean rust in Brazil, it is clear PHC279 will have important benefits for farmers in many crops. The registration of our first PREtec peptide is progressing in the US and Brazil and the scale-up of manufacturing has started. We are excited about the potential for products based on our PREtec peptides, which are targeting markets with an initial opportunity of $5 billion. We aim to launch the first peptides as soon as regulatory permits have been obtained, to offer these valuable new tools to growers in the US and other countries."

For further information, please contact:

Plant Health Care plc

Chris Richards, CEO Tel: +1 919 926 1600

Arden Partners plc – Nomad & Broker

John Llewellyn-Lloyd / Dan Gee-Summons Tel: +44 (0) 20 7614 5900

Company website: www.planthealthcare.com

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

UPDUNAORROUVUAR

Close

26 MAY 2020

Tracsis PLC : Contract Wins

RNS Number : 8176N Tracsis PLC 26 May 2020 26 May 2020 Tracsis plc ("Tracsis" or the "Group") Large Rail Contract Wins Tracsis, a leading provider of software, hardware and services for the rail, traffic data and wider transport industries, is pleased to announce that it has been……

RNS Number : 8176N

Tracsis PLC

26 May 2020

Tracsis plc

("Tracsis" or the "Group")

Large Rail Contract Wins

Tracsis, a leading provider of software, hardware and services for the rail, traffic data and wider transport industries, is pleased to announce that it has been awarded two major rail contracts.

The first award is a further significant contract for the provision of its TRACS Enterprise software product with another major UK rail operator. The contract will be delivered over multiple years and is for several million pounds, which includes the renewal of some existing systems already licenced by the customer, plus significant levels of additional functionality through the TRACS Enterprise suite, including the ATTUne timetabling software that was added to the Group via the acquisition of Bellvedi Limited in April 2019.

The contract will not have a major financial impact in the current financial year ending 31 July 2020 but helps to underpin our confidence for the future, and the product suite that has been in significant development in recent years.

The second win is a major order for the provision of remote condition monitoring technology, plus our associated Centrix software and related support services, to an existing customer. The contract is for several hundred thousand pounds, and will be delivered over the coming months.

The Rail Technology and Services division continues to operate with high activity levels, and continues to pursue a number of other new opportunities across its range of software offerings.

Chris Barnes, Chief Executive Officer, commented:

"We are delighted to have secured these major contracts with two major UK rail customers and look forward to delivering these projects in the months to come. The UK rail industry continues to adopt our award winning TRACS Enterprise software and remote condition monitoring technology, both of which can bring significant benefits to the operators, and these latest wins are testament to the strength of our team and quality of our market leading products."

Enquiries:

Tracsis plc Tel: 0845 125 9162

Chris Barnes, CEO

Max Cawthra, CFO

finnCap Ltd Tel: 020 7220 0500

Christopher Raggett/Charlie Beeson, Corporate Finance

Andrew Burdis, Corporate Broking

Notes to editors:

· Tracsis plc is a technology company and a leading provider of software and hardware products, data capture and data analytic services for the rail, traffic data and wider transport industries.

· Tracsis' products and services are widely used to increase efficiency, reduce cost and risk and improve operational and asset performance, safety management and decision making capabilities for clients and customers.

· The Group is split into two principle operating areas built around detailed industry knowledge and expertise:

– Rail Technology & Services: Software and technology led business supported by consultancy. Develops remote condition monitoring hardware and safety, productivity improvement, risk management and data acquisition software for rail infrastructure providers and software that solves complex resource, asset optimisation and control problems for Train Operators.

– Traffic & Data Services: A largely services led business that focuses on data capture, data analytics, data insights and event traffic management within transport and pedestrian rich environments. The business provides technology and data that underpins large scale intelligent transport system and smart city planning and decision making.

· Tracsis has a blue-chip client base which includes all major UK transport owning Groups. The business also works extensively with Network Rail, the Department of Transport, TfL, multiple local authorities, major outdoor music and sporting event organisers, and a wide variety of large engineering and infrastructure companies.

· The business drives growth both organically and through acquisition and has made fourteen acquisitions since 2008.

· For more information on Tracsis please visit http://www.tracsis.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

CNTFIFEDELISFII

Close

26 MAY 2020

Panoply Holdings PLC : Contract win trading update and webinar

RNS Number : 8337N Panoply Holdings PLC (The) 26 May 2020 26 May 2020 The Panoply Holdings PLC ("The Panoply", the "Group", and the "Company") Contract win, trading update and private investor webinar The Panoply (AIM: TPX), a digitally native technology-enabled services company, is pleased to announce……

RNS Number : 8337N

Panoply Holdings PLC (The)

26 May 2020

The Panoply Holdings PLC

("The Panoply", the "Group", and the "Company")

Contract win, trading update and private investor webinar

The Panoply (AIM: TPX), a digitally native technology-enabled services company, is pleased to announce that Group business FutureGov has signed a significant digital transformation contract with a large, global philanthropic organisation.

This contract, which is worth a total of US$5.2m over 14 months, will see FutureGov supporting the organisation's teams across EU capital cities to focus on and transform local government services in order to deliver better outcomes. Using its extensive experience and expertise in the digital transformation sector, FutureGov will produce bespoke, digitally-enabled community focused services that seek to address current major issues facing communities.

This contract is another success for the Group in the public sector, further demonstrating the strength of the Group's offering in this field, the importance of its purpose-driven work and also its ability to continue securing significant new business wins even during this time of heightened uncertainty.

Trading update

Coming into the current financial year, the Group had a confirmed backlog deliverable in the year, including annualised recurring revenue, of approximately £15m. The contract with the philanthropic organisation is one of a number of new business wins the Group has signed in the last eight weeks (since 1 April 2020), which comprises a total value of £9.5m, the majority of which will be delivered this financial year.

The Group expects to report a strong performance for the first quarter of FY21 with year-on-year organic growth on a like-for-like pro forma basis*. Margins are expected at pre-COVID-19 levels, driven by the volume of new work secured. Alongside this the Group expects continued profitability and strong cash generation.

Whilst the uncertainty created by the COVID-19 pandemic means it remains very difficult to predict performance going forward, the Group remains confident in its market offering that spans technology, design and strategy, with around 70% of pro forma revenues now coming from public services.

*Q1 FY20 revenue on a pro forma basis, including Ameo and FutureGov, would have been approximately £9.1m. Ameo and FutureGov have been included to show a true like-for-like comparison.

Investor webinar

Further to this update, The Panoply's CEO, Neal Gandhi and CFO Oliver Rigby will be hosting a private investor webinar on Tuesday, 2 June 2020 at 14.00. Registration for the webinar is available via the following link: https://bit.ly/TPX_Update

Issue of consideration shares

As announced on 28 April 2020, the acquisitions made by the Group to date have traded in line with expectations and so it is anticipated that further consideration in line with previous guidance of approximately £17m will become payable. This consideration will become payable following the release of the Group's FY20 results, expected to be in July 2020, and will result in the issue and allotment of c.21.5m new shares in The Panoply. This represents c.40% of the current issued share capital.

Neal Gandhi, CEO of The Panoply commented:

"We always believed that our aim of being purposeful in our approach would deliver great financial returns. This has been proven so far this year with the group winning £9.5m in new work since April 1st, an eight week period that for many has been the most challenging in living memory. I'm immensely grateful to our people who have gone above and beyond in order to deliver what looks set to be a record Q1 with organic growth on a like for like basis.

I would particularly like to mention our teams that have been involved in COVID-19 emergency response related projects. They have worked tirelessly to deliver projects in difficult circumstances that have contributed to ensuring those most in need of help have received it."

Enquiries:

The Panoply Holdings

Neal Gandhi (CEO)

Oliver Rigby (CFO)

Via Alma PR

Stifel

(Nomad and Broker)

Fred Walsh

Alex Price

+44 (0)207 710 7600

Alma PR

(Financial PR)

Josh Royston

Susie Hudson

[email protected]

+44(0)203 405 0206

07780 901979

About The Panoply

The Panoply is a digitally native technology services company, built to service clients' digital transformation needs. Founded in 2016, with the aim of identifying and acquiring best-of-breed specialist information technology, design and innovation consulting businesses across Europe, the Group collaborates with its clients to deliver the technology outcomes they're looking for at the pace that they expect and demand.

More information is available at www.thepanoply.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TSTAAMLTMTJTBRM

Close